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Abstract. Functional diffusion mapping (fDM) is a cancer 
imaging technique that quantifies voxelwise changes in 
apparent diffusion coefficient (ADC). Previous studies have 
shown value of fDMs in bevacizumab therapy for recurrent 
glioblastoma multiforme (GBM). The aim of the present study 
was to implement explicit criteria for diffusion MRI quality 
control and independently evaluate fDM performance in a 
multicenter clinical trial (RTOG 0625/ACRIN 6677). A total of 
123 patients were enrolled in the current multicenter trial and 
signed institutional review board-approved informed consent 
at their respective institutions. MRI was acquired prior to and 
8 weeks following therapy. A 5-point QC scoring system was 
used to evaluate DWI quality. fDM performance was evaluated 
according to the correlation of these metrics with PFS and OS 
at the first follow-up time-point. Results showed ADC vari-
ability of 7.3% in NAWM and 10.5% in CSF. A total of 68% 
of patients had usable DWI data and 47% of patients had high 
quality DWI data when also excluding patients that progressed 
before the first follow-up. fDM performance was improved 
by using only the highest quality DWI. High pre-treatment 
contrast enhancing tumor volume was associated with shorter 
PFS and OS. A high volume fraction of increasing ADC after 
therapy was associated with shorter PFS, while a high volume 
fraction of decreasing ADC was associated with shorter OS. 
In summary, DWI in multicenter trials are currently of limited 
value due to image quality. Improvements in consistency of 
image quality in multicenter trials are necessary for further 
advancement of DWI biomarkers.
Introduction
Approximately 20.6 people per 100,000 people in the United 
States are diagnosed with a primary brain tumor each year (1). 
GBM constitutes the most common and aggressive form of 
malignant glioma, occurring in ~54% of gliomas (1) or 3.2 
per 100,000 US citizens, and carrying a dismal prognosis of a 
median survival of around 14 months (2) with <10% of patients 
surviving beyond 5 years after diagnosis. Currently, the stan-
dard of care for newly diagnosed GBM patients consists of 
maximum surgical resection, followed by radiotherapy plus 
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concomitant and adjuvant temozolomide. At recurrence, 
however, very few therapeutic options exist. Currently, no 
treatment regimens have produced considerable therapeutic 
benefit in recurrent GBM (3).
Bevacizumab, a monoclonal antibody to vEGF (4) is now 
a common second-line treatment option for GBM patients that 
have failed the standard of care, particularly due to an apparent 
progression-free survival benefit shown in early clinical trials 
(5-7) compared with historic controls (2). These early results 
were based on a modified Macdonald criteria (8), which is 
limited in the evaluation of anti-angiogenic treatments due 
to the dramatic effect on vascular permeability resulting in 
decreased contrast enhancement (9,10). Diffusion-sensitive 
magnetic resonance imaging (MRI) biomarkers have shown 
some early promise as predictive tools (11) in bevacizumab 
therapy at recurrence. In particular, the functional diffusion 
map (fDM) technique, which evaluates voxel-wise changes in 
the apparent diffusion coefficient (ADC) over time, has shown 
utility as an early response biomarker in bevacizumab therapy 
in a single institution dataset consisting of uniform, high-
quality diffusion MRI data (11). This technique, however, has 
not been evaluated in the context of a large multicenter trial 
with mixed quality of diffusion MRI data.
The aim of the present study was to implement explicit 
criteria for quality control and evaluate fDM performance 
using DWI data collected as part of RTOG-0625, a multicenter, 
randomized, phase II trial of bevacizumab with irinotecan or 
temozolomide in recurrent GBM.
Materials and methods
The Radiation Therapy Oncology Group (RTOG), in collabo-
ration with the American College of Radiology Imaging 
Network (ACRIN), both funded by the National Cancer 
Institute, conducted a prospective, randomized, phase II multi-
center trial comparing bevacizumab with either irinotecan 
or temozolomide treatment in recurrent GBM (RTOG 0625/ 
ACRIN 6677; ClinicalTrials.gov #NCT00433381; NCI-2009-
00743). Twenty-four institutions both participated and had 
diffusion MRI data available for analysis, each obtaining 
institutional review board approval before subject accrual and 
conducting the trial with Health Insurance Portability and 
Accountability Act (HIPAA) compliance. Informed consent 
was obtained for all subjects.
Study subjects. A total of 123 patients were enrolled in the 
current trial (Table I). All patients had recurrent histologi-
cally proven GBM or gliosarcoma with progression on MRI 
within 14 days after registration, ≥42 days after completion 
of radiation/temozolomide therapy, ≥28 days after surgical 
resection or cytotoxic therapy, as well as imaging or biopsy 
confirmation of true progressive disease rather than radiation 
necrosis after Gliadel placement or stereotactic radiosurgery. 
Detailed inclusion and exclusion criteria are available at 
http://www.acrin.org/Portals/0/Protocols/6677/RTOG%20
062-ACRIN%206677.pdf (Section 3.0). Bevacizumab was 
administered to all patients (10 mg/kg intravenously, days 1 
and 15 of a 28-day cycle). In the first arm, patients received 
temozolomide (75 mg/m2 per os, days 1-21 during the first 
28-day cycle; 100 mg/m2 for cycle 2 and beyond in the absence 
of myelotoxicity). In the second arm, patients received irino-
tecan (125 mg/m2 intravenously, days 1 and 15 of a 28-day 
cycle). Standard of care MRI occurred at baseline, after every 
2 cycles of treatment (every 8 weeks), and after completion 
or termination of treatment. Patients demonstrating benefit 
(stable or responding tumor) were treated for 12 cycles with 
optional extension to 24 cycles in the presence of continued 
benefit and absence of severe toxicity.
Magnetic resonance imaging. Conventional MRI included pre-
contrast T1-weighted, T2-weighted, T2-weighted FLAIR, and 
diffusion-weighted MRI (DWI). After intravenous injection of 
0.1 mmol/kg of standard gadolinium-based contrast, an axial 
2D spin-echo and 3D volumetric T1-weighted (T1+C) images 
were acquired. Patients participating in the optional advanced 
component of the trial had dynamic contrast-enhanced MRI, 
dynamic susceptibility contrast perfusion-weighted MRI, 
and/or MR spectroscopy at baseline, week 2 and after every 2 
cycles of treatment.
Diffusion MR acquisition parameters varied widely across 
institutions despite specific ACRIN recommendations. echo 
time (Te) varied from 64 to 111.9 ms (~200%), and by as 
much as 50% in the same patient during follow-up evalua-
tions. Repetition time (TR) varied from 6 to 10 sec (~50%), 
b-values ranged from 0 and 700 to 0 and 1,200 sec/mm2, and 
Table I. Summary of sites and number of patients enrolled.
 No. of
Site patients
4205 - Barnes jewish Hospital 7
4212 - Thomas Jefferson 2
4214 - MD Anderson 19
4217 - University of Iowa 2
4219 - Sloan Kettering 6
4220 - University of Rochester 1
4254 - Medical College of Wisconsin 3
4275 - Henry Ford 22
4283 – Akron General Medical Center 2
4372 - St. john's Health System 1
4399 - St. luke's 5
4400 - Tel-Aviv Medical Center 13
4403 - Mt. Diablo 1
4404 - jFK 1
4405 - lDS 7
4406 - Arizona Oncology Serv @ SjHMC 1
4407 - virginia Mason Medical Center 5
4409 - Carolina's Medical Center/levine Cancer Ctr 6
4411 - N. Rockies Regional Cancer Center 1
4413 - Anne Arundel Medical Center 3
4414 - Alta Bates Comprehensive Cancer Center 1
4470 - Yale University 1
4492 - University of Chicago 12
4494 - UCLA 1
Total 123
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in some cases diffusion tensor imaging (6-12 directions) was 
also acquired. In order to ensure relative consistency of ADC 
calculations across sites, measures of ADC were obtained from 
2 b-values (typically a single b=0 sec/mm2 image and an image 
with higher diffusion weighting, or b=700-1200 sec/mm2. For 
DTI data, average trace images were used for this higher diffu-
sion weighted image).
Image registration. All images for each patient were registered 
to their own pre-treatment, post-contrast, 3D T1-weighted 
images with use of a mutual information algorithm and a 
12-degree of freedom transformation using FSl (FMRIB; 
http://www.fmrib.ox.ac.uk/fsl/). This was followed by visual 
inspection to ensure adequate alignment. All images were 
interpolated to the resolution of baseline post-contrast 
T1-weighted images using trilinear interpolation. In cases with 
significant mass effect, attempts were made to align tumor 
regions exclusively. Regions of obvious misregistration (e.g. 
near ventricles or edge of the brain) were excluded from final 
fDM analysis.
Quantitative quality control evaluation of diffusion MR data 
and image registration. Quality control (QC) evaluation was 
performed on both the diffusion MR data as well as the align-
ment between subsequent scans for use in fDM analysis. DWI 
at each scan date were evaluated in terms of the following 
factors: i) geometric distortion or artifacts on diffusion MR 
datasets; ii) ADC values within normal appearing white matter 
(NAWM) being within an acceptable range of ~0.4-1.0 µm2/ms; 
and iii) ADC values within cerebrospinal fluid (CSF) being 
within an acceptable range of ~2.5-4.0 µm2/ms. A 5-point 
quantitative scaling scheme was used for each of these factors 
as shown in Table II. The final QC score for each patient was 
calculated as the minimum QC value from each of the param-
eters in Table II. Additionally, if DWI data were not available 
for a particular patient, the QC score was zero.
Region of interest (ROI) determination. In the present study, 
we chose to apply fDMs to regions of contrast-enhancing 
tumor on pre-treatment, post-contrast T1-weighted images. 
This approach has been shown to be the most predictive in 
other treatment settings (11,12). Additionally, this time-point 
likely contains the largest extent of contrast enhancing tumor 
for use in fDM evaluation, since bevacizumab therapy results 
in dramatic reduction of the volume of contrast enhancement in 
the majority of patients. We used a semi-automated process of: 
i) manually defining the relative region of tumor occurrence; 
ii) thresholding the post-contrast images using an empirical 
threshold combined with a region-growing algorithm; then iii) 
manually editing the resulting masks to exclude any obvious 
errors. For QC evaluations, a circular ROI (area, 1.5 cm2 or 
~1.4 cm diameter) was placed in the contra-lateral NAWM and 
within the contra-lateral, anterior or posterior lateral ventricles 
for a measure of normal CSF.
Functional diffusion map (fDM) calculation. After proper 
registration was visually verified, voxel-wise subtraction was 
performed between ADC maps acquired post-treatment and 
baseline, pre-treatment ADC maps. Individual voxels were 
stratified into three categories based on the change in ADC 
relative to the baseline ADC map. Red voxels represented 
areas where ADC increased beyond a ∆ADC threshold of 
0.4 µm2/ms, or ADC(+), and blue voxels represented areas 
where ADC decreased beyond a ∆ADC threshold of 0.4 µm2/ms 
or ADC(-). These ∆ADC thresholds (±0.40 µm2/ms) represent 
the 95% confidence interval for a mixture of normal appearing 
gray and white matter estimated from 69 patients with various 
tumor grades and follow-up time intervals ranging from 
Table II. Quantitative quality control definitions for diffusion MRI and fDM analysis.
Parameter Score = 1 Score = 2 Score = 3 Score = 4 Score = 5
 (Unusable) (Unusable) (Usable) (Good) (Great)
Distortion/artifacts Severe,  Moderate,  Moderate, not Mild, not No distortion or
 affecting tumor affecting tumor affecting tumor affecting tumor artifacts
ADC values Negative values Non-physiological Lower or higher  Within normal range
(NAWM)  range (0-0.4 µm2/ms) than normal,   (0.6-0.8 µm2/ms)
   but within
   physiological range
   (e.g. 0.4-0.6 µm2/ms;
   0.8-1.0 µm2/ms)
ADC values (CSF) Negative values Non-physiological lower or higher  Within normal range
  range (0-1.5 µm2/ms;  than normal,  for CSF
  4.0+ µm2/ms) but within
   physiological range
Registration of ADC Severe  Moderately  Moderately  Slightly  Perfectly aligned
maps with misalignment, misaligned,  misaligned, but misaligned,
Baseline tumor not aligned tumor not aligned tumor is aligned but tumor
ADC maps    is largely aligned
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1 week to 1 year post-baseline (13). The fraction of ADC(+) and 
ADC(-) within the pre-treatment, post-contrast T1-weighted 
images [%ADC(+) and %ADC(-)] was subsequently used for 
fDM analysis.
Independent radiological facility definition of disease 
progression. All local imaging was retrospectively trans-
mitted to ACRIN for central review. Two primary readers 
and one adjudicator, each with neuroradiology Certificates of 
Added Qualification and 8, 6 and 3 years of post-fellowship 
experience, respectively, were trained via teleconference 
about 2D measurement techniques. each primary reader was 
assigned 2 similarly trained core laboratory technologist and 
conducted independent image assessments. For each distinct 
contrast-enhancing target lesion as defined by Macdonald and 
RANO criteria (≥1 cm diameter, ≥1 cm from other enhancing 
lesions), the largest diameter of contrast enhancement and its 
maximum perpendicular diameter in the same plane were 
measured. 2D tumor area was computed by summing over 
all lesions the product of maximum perpendicular diameters. 
Each reader determined time of progression on 2D post-
contrast T1-weighted images when there was >25% increase 
with respect to nadir in maximal cross-sectional enhancing 
areas or the appearance of any new enhancing tumor (9,14). 
Similarly, radiologic response was defined as ≥50% decrease 
with respect to baseline, confirmed on the subsequent time-
point. Steroid dosage and clinical status were unavailable to 
ACRIN readers for the present study. The adjudicator settled 
discordant times to progression between primary readers by 
selecting the times to progression that were most correct in 
their opinion. The final measure of progression-free survival 
(PFS) for the present study was defined as the time from the 
first post-therapy scan used in fDM analysis until radiographic 
progression.
Statistical analysis. A Kruskal-Wallis non-parametric test 
was used to compare ADC measurements in normal tissue 
across sites with 3 or more patients. Pooled variance two-
sample t-tests were used to compare pre-treatment enhancing 
tumor volume, %ADC(+), or %ADC(-) between patients who 
progressed/expired vs. were progression-free at 6 months and 
those who expired at 12 months vs. those who were alive at 
12 months from the first post-treatment MRI. Two-sample 
Satterthwaite t-tests were used if group variances were signifi-
cantly different. A Cox-regression model was used to evaluate 
continuous measures of pre-treatment enhancing volume, 
%ADC(+) or %ADC(-) adjusted for age and gender, where 
the outcome was either PFS or overall survival (OS). Time-
dependent receiver operating characteristic (ROC) analysis 
was performed for PFS or OS to determine the thresholds 
for %ADC(+) and %ADC(-) that maximized Youden's index 
(sensitivity+specificity-1). The threshold values were used 
to divide %ADC(+) or %ADC(-) into two groups. Median 
PFS and OS as well as their curves within each group were 
estimated by the Kaplan-Meier method. log-rank tests were 
conducted to compare the PFS (or OS) curves between the two 
groups of %ADC(+) [or %ADC(-)]. Data were examined sepa-
rately for all usable DWI cases (QC ≥3) and cases with high 
quality DWI data (QC=5) to illustrate the effects of image 
quality on fDM analyses. P-values <0.05 were considered 
significant and P-values <0.1 were considered trending toward 
significance. All statistical data analyses were performed with 
SAS software, version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Normal tissue ADC and quality control assessment. The eval-
uation of pre-treatment ADC measurements within normal 
tissues for different sites, MR manufacturers, and acquisition 
techniques are shown in Fig. 1. In general, there was a wide 
variation in diffusion measurements within the various tissue 
types. The average coefficient of variance across all sites was 
7.3% for NAWM and 10.5% for CSF. Kruskal-Wallis non-
parametric comparisons of CSF and NAWM in sites with 3 
or more patients suggested ADC varied significantly across 
sites (NAWM, P<0.001; CSF, P<0.001). Closer examination 
suggested that certain sites had systematically elevated or 
suppressed estimates of ADC within normal tissues.
Of the 123 patients with diffusion data available, 84 
patients (68%) had adequate image quality (QC score ≥3) and 
58 patients (47%) had high quality data (QC score =5). Fig. 2 
shows example diffusion MR images from patients for various 
QC scores. The average QC score for all 123 patients was 3.37. 
Of the 84 patients with adequate diffusion MR information, 
ACRIN determined 3 cases ineligible for analysis, 3 cases 
were withdrawn due to no evaluable contrast-enhancing tumor, 
2 cases were excluded due to no baseline MR scan after regis-
tration to 6677, and 12 patients progressed prior to the first 
imaging time-point, resulting in a total of 64 patients (52%) 
of total enrolled patients with evaluable data for fDM analysis 
(QC score ≥3) and a total of 46 patients (37%) of total enrolled 
patients with high quality fDM data (QC score=5).
Study cohort and general fDM characteristics. Of the 64 
patients with diffusion MR data available for fDM analysis 
(QC ≥3), 34 patients were male and the mean age for all 
patients was 57.3 years old ±11.2 SD. The average pre-treat-
ment contrast enhancing volume was 18.5±16.9 cc SD, average 
%ADC(+) was 17.8±14.4% SD, and average %ADC(-) was 
20.6±17.9% SD.
Fig. 3 illustrates various examples of fDM response to 
therapy, which in many cases appeared independent of changes 
in anatomical images. For example, the patient in Fig. 3A 
showed little change in contrast enhancement after therapy, 
suggestive of stable disease or little response to therapy. fDM 
results in this patient showed a relatively large proportion of 
tumor with decreasing ADC (blue voxels), possibly suggestive 
of growing tumor or increasing cell density. Conversely, the 
patient shown in Fig. 3B demonstrated a similar change in 
anatomical imaging response, but little change on fDMs. Some 
patients showed a dramatic decrease in contrast enhancement 
following therapy and little change in ADC, such as the patient 
shown in Fig. 3C. Other patients showed a decrease in contrast 
enhancement that was accompanied by an increase in ADC 
(red voxels) similar to the patient shown in Fig. 3D.
Progression-free survival (PFS)
Patients with DWI QC ≥3. A total of 60 of 64 patients either 
progressed or expired at the time of final evaluation, while 
43 of 64 patients either progressed or expired at 6 months 
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from the first post-treatment time-point. Patients who were 
progression-free at 6 months showed no significant differences 
in pre-treatment volume of contrast enhancement and fDM 
characteristics from those who progressed or expired before 6 
months (P>0.05). Continuous measures of enhancing volume 
were not significantly correlated with PFS (Cox regression: 
Figure 1. Mean ADC estimates for cerebrospinal fluid (CSF) and normal-appearing white matter (NAWM) across different sites, scanner manufacturers, and 
field strengths. Kruskal-Wallis non-parametric comparisons of CSF and NAWM in sites with 3 or more patients suggested ADC varied significantly by site 
(P<0.0001), with some sites showing systematically higher or lower ADC values in normal tissues.
Figure 2. example images for QC scores resulting from varying degrees of geometric distortion in ADC maps. QC score = 5 (great) reflects high-quality 
diffusion MRI data with no distortions. QC score = 4 (good) reflects mild geometric distortion that does not affect the tumor. QC score = 3 (usable) reflects 
moderate geometric distortion not affecting the tumor. QC score = 2 (unusable) involves images with moderate distortion that is affecting measurement of the 
tumor. QC score = 1 (unusable) involves severe distortion that is affecting measurement of the tumor. 
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age, P=0.153; gender, P=0.214; pre-treatment enhancing 
volume, P=0.130); however, stratification of patients by median 
pre-treatment volume of contrast enhancement (14.9 cc) did 
show significant stratification of PFS (Fig. 4A; log-rank, 
P=0.003). Continuous measures of %ADC(+) and %ADC(-) 
from fDM analysis were not significantly correlated with PFS 
when adjusted for age and gender (Cox regression; P>0.05 
for both %ADC(+) and %ADC(-)]. Youden's index suggested 
Figure 3. examples of anatomical imaging and fDM response to bevacizumab and irinotecan or temozolomide. (A) This patient demonstrates a small change 
in enhancing tumor volume, but a relatively large proportion of the tumor with decreasing ADC (blue voxels). (B) This patient shows a similar change in 
enhancing tumor to the patient in (A), but shows very little change in ADC. (C) A patient with a dramatic change in contrast enhancement following therapy 
that is not accompanied by a substantial change in ADC. (D) A patient with a decrease in contrast enhancement that involves a large proportion of the tumor 
with increasing ADC (red voxels). Red voxels = ∆ADC >+0.4 µm2/ms; blue voxels = ∆ADC <-0.4 µm2/ms; green voxels = -0.4 µm2/ms ≤∆ADC ≤+0.4 µm2/ms.
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Figure 4. Pre-treatment contrast enhancing tumor volume and fDM response correlation of progression-free survival (PFS) for usable (QC ≥3) and high quality 
(QC=5) DWI data. (A) Stratification of PFS based on pre-treatment contrast enhancing volume (T1+C) in patients with usable DWI data (log-rank, P=0.0026). 
(B) Stratification of PFS based on the volume fraction of enhancing tumor with an increase in ADC [%ADC(+)] in patients with usable DWI data (log-rank, 
P=0.103). (C) Stratification of PFS based on the volume fraction of enhancing tumor with a decrease in ADC [%ADC(-)] in patients with usable DWI data 
(log-rank, P=0.166). (D) Stratification of PFS based on T1+C in patients with high quality DWI data (log-rank, P=0.0106). (e) Stratification of PFS based on 
%ADC(+) evaluated in patients with high quality DWI data (log-rank, P=0.0421). (F) Stratification of PFS based on %ADC(-) evaluated in patients with high 
quality DWI data (log-rank, P=0.121).
Figure 5. Pre-treatment contrast enhancing tumor volume and fDM response correlation with overall survival (OS) for usable (QC ≥3) and high quality 
(QC=5) DWI data. (A) Stratification of OS based on pre-treatment contrast enhancing volume (T1+C) in patients with usable DWI data (log-rank, P=0.125). 
(B) Stratification of OS based on volume fraction of enhancing tumor with an increase in ADC [%ADC(+)] in patients with usable DWI data (log-rank, 
P=0.158). (C) Stratification of OS based on volume fraction of enhancing tumor with a decrease in ADC [%ADC(-)] in patients with usable DWI data (log-rank, 
P=0.219). (D) Stratification of OS based on T1+C evaluated for patients with high quality DWI data (log-rank, P=0.099). (e) Stratification of OS based on 
%ADC(+) in patients with high quality DWI data (log-rank, P=0.668). (F) Stratification of OS based on %ADC(-) evaluated in patients with high quality DWI 
data (log-rank, P=0.0346).
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an optimal cutpoint of %ADC(+) of 20.5% and %ADC(-) of 
2.7% for PFS. Using these thresholds, patients with a large 
volume fraction of pre-treatment enhancing tumor with 
increasing ADC, or %ADC(+) >20.5 cc, had slightly worse 
PFS (median PFS = 167 vs. 98 days); however, this was not 
statistically significant (Fig. 4B; log-rank, P=0.103). Results 
also suggest patients with a large volume fraction of pre-treat-
ment enhancing tumor with decreasing ADC at follow-up, or 
%ADC(-) >2.7, had a slightly shorter PFS (median PFS = 107 
vs. 240 days), but this was also not statistically significant 
(Fig. 4C; log-rank, P=0.116).
Patients with DWI QC=5. For patients with high quality 
DWI data, a significant difference in pre-treatment contrast 
enhancing volume was observed between patients who 
were progression-free at 6 months and those who expired 
or progressed before 6 months (11.6 vs. 19.9 cc, P=0.027), 
but no significant differences were found in fDM char-
acteristics between these patients (P>0.05). Continuous 
measures of pre-treatment contrast-enhancing tumor volume 
were significantly correlated with PFS (Cox regression: 
age, P=0.196; gender, P=0.810; pre-treatment enhancing 
volume, P=0.012). Consistent with these trends, stratifica-
tion of patients by median pre-treatment volume of contrast 
enhancement (14.3 cc) demonstrated significant stratification 
of PFS (Fig. 4D; log-rank, P=0.011). Continuous measures of 
%ADC(+) and %ADC(-) from fDM analysis were not signifi-
cant predictors for PFS when accounting for age and gender 
[Cox regression: P>0.05 for both %ADC(+) and %ADC(-)]. 
Youden's index suggested a threshold of %ADC(+) of 27.4% 
and %ADC(-) of 2.7% for PFS in patients with high quality 
DWI. Results suggest patients with a large volume fraction 
of pre-treatment enhancing tumor with increasing ADC or 
%ADC(+) >27.4%, had significantly shorter PFS (Fig. 4e; 
median PFS =77 vs. 120 days; log-rank, P=0.042). Results 
also suggest patients with a large volume fraction of pre-
treatment enhancing tumor with decreasing ADC at follow-up 
or %ADC(-) >2.7%, had a slightly shorter PFS (median PFS 
= 107 vs. 240 days), but this was not statistically significant 
(Fig. 4F; log-rank, P=0.121).
Overall survival (OS). A total of 56 of 64 patients with 
evaluable DWI expired by the end of the study, while 45 of 
64 patients expired by 12 months from the first post-treatment 
time-point. No difference in mean pre-treatment contrast 
enhancing volume or fDM characteristics were observed 
between patients alive at 12 months compared with those who 
expired at 12 months (P>0.05 for all metrics).
Patients with DWI QC ≥3. Neither continuous measures of 
enhancing volume or fDM characteristics were significant 
predictors for OS [Cox, P>0.05 for volume, %ADC(+) and 
%ADC(-)]. When patients were stratified by median pre-
treatment contrast-enhancing tumor volume (14.9 cc), no 
significant difference in OS was observed (Fig. 5A; log-rank, 
P=0.125). Th optimal cutpoints for %ADC(+) and %ADC(-) 
were 17.3 and 26.2% when the outcome was OS; however, 
neither %ADC(+) (Fig. 5B; log-rank, P=0.158) nor %ADC(-) 
(Fig. 5C; log-rank, P=0.219) significantly separated these 
groups in terms of OS.
Patients with DWI QC=5. For patients with high quality DWI 
data available, continuous measures of pre-treatment contrast-
enhancing tumor was significantly correlated with OS (Cox, 
P=0.006 for volume, P=0.080 for age and 0.575 for gender). 
When patients were stratified by median pre-treatment 
enhancing volume (14.3 cc), a trend toward a difference in 
OS was observed (Fig. 5D; log-rank, P=0.099). Continuous 
measures of %ADC(+) and %ADC(-) were not significantly 
associated with OS (Cox, P>0.05 for fDM metrics). The 
optimal cutpoints for %ADC(+) and %ADC(-) in patients with 
high quality DWI data were 15.2 and 3.97%, respectively. The 
Kaplan-Meier curves between the two groups of %ADC(+) 
were not significantly different (Fig. 5e; log-rank, P=0.668). 
On the other hand, patients with a large volume fraction of pre-
treatment enhancing tumor with decreasing ADC at follow-up, 
or %ADC(-) >3.97%, had a significantly shorter OS (Fig. 5F; 
median OS = 210 vs. 413 days; log-rank, P=0.035).
Discussion
To the best of our knowledge, this is one of the first studies 
to define and implement specific diffusion MRI quality 
control criteria in the setting of a multicenter clinical trial 
in brain cancer. Results from the present study showed 
~7.3-10.5% coefficient of variance in measurement of ADC 
across various sites. These results appear consistent with the 
measurements obtained by Chenevert et al (15), who esti-
mated the variability of ADC in an ideal setting of an ice 
water phantom at ~5% when evaluated across vendors and 
platforms. It is important to note, however, that measures 
of ADC within a water phantom is monoexponential, thus, 
measurements of ADC may be quite resilient to the number 
of b-values and maximum b-value chosen, which may not be 
the case with normal neural tissues. More importantly, only 
84 of the original 123 (68%) patients had usable DWI data 
free of distortion around the areas of tumor and only 58 of 
the original 123 (47%) patients had high quality DWI data 
with no distortions or ADC abnormalities. [In the end, only 
64 patients (52%) had usable DWI data and 46 patients (37%) 
had high quality DWI data after patients were excluded based 
on other factors]. This degree of unusable data is particularly 
discouraging if diffusion MRI is to be considered a secondary 
response biomarker or a potential imaging endpoint in future 
prospective multicenter clinical trials.
The present study clearly demonstrates the importance of 
performing semi-quantitative QC in the context of advanced 
imaging in multicenter clinical trials. Functional diffusion 
mapping using high quality diffusion MRI acquired before 
and after administration of bevacizumab is a valuable imaging 
biomarker for predicting survival in recurrent glioblastoma 
patients treated with bevacizumab. Almost all fDM metrics 
showed improved stratification of short- and long-term PFS 
and OS when examining the highest quality DWI data (QC=5) 
compared with usable DWI data (QC ≥3). In particular, 
examination of high quality DWI data showed significant 
stratification of short- and long-term PFS when examining 
the volume fraction of pre-treatment enhancing tumor with 
increasing ADC [%ADC(+)], while the volume fraction of 
enhancing tumor with decreasing ADC [%ADC(-)] showed 
significant stratification of short- and long-term OS. When 
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examining only the usable DWI data (QC ≥3), these trends 
were not statistically significant.
Although only a subset of data was evaluable in the present 
multicenter study, fDM results appeared to show some trends 
that were consistent and other trends that were inconsistent 
with previous studies. For example, previous fDM studies 
involving radiochemotherapy (12,16,17) in newly diagnosed 
malignant gliomas and bevacizumab (11) in recurrent GBM 
showed that patients with a low volume fraction of tumor with 
decreasing ADC [%ADC(-)] were more likely to have a longer 
PFS and OS. In the present study, we observed the same trend, 
however, results only showed statistical significance when 
examining %ADC(-) in terms of OS the subset of patients with 
high quality DWI data. Contrary to previous fDM reports, 
patients exhibiting a large volume fraction of enhancing 
tumor demonstrating an increase in ADC at first follow-up 
[%ADC(+)] appeared more likely to progress earlier than 
patients with a small volume fraction. Since all these patients 
were treated with bevacizumab, which tends to rapidly reduce 
the amount of vasogenic edema, it is conceivable that tumors 
demonstrating an increase in ADC following bevacizumab 
may represent those tumors to which vascular permeability 
has increased, indicating ineffective anti-angiogenic therapy.
It is important to point out that pre-treatment contrast 
enhancing tumor volume was one of the strongest correlates of 
survival in recurrent GBM patients treated with bevacizumab 
and chemotherapy. Results from the present study suggest that 
continuous measures of pre-treatment enhancing tumor were 
significantly correlated with PFS and OS when accounting for 
clinical covariates, particularly when examining patients with 
the highest quality MR data. This observation is consistent 
with a recent study (18) examining contrast enhancing tumor 
before and after bevacizumab treatment in a similarly struc-
tured phase II multicenter study in recurrent GBM patients 
treated with bevacizumab monotherapy or bevcizumab and 
irinotecan. As measures of contrast enhancing tumor remain 
the gold standard for response assessment and estimating 
tumor burden in malignant gliomas, it is important to compare 
emerging imaging biomarkers with this standard to determine 
if they truly add clinical benefit.
A number of limitations and possible explanations for the 
relatively poor fDM performance should be addressed. First, 
the present study involved calculation of ADC given only 2 
b-values, while the National Cancer Institute recommends that 
at least 3 b-values be acquired (0, >100 and >500 sec/mm2) 
for estimation of perfusion-insensitive ADC (19). Additionally, 
many sites did not comply with the recommended diffusion 
MRI protocols, nor was there a mechanism in place for 
real-time feedback of image quality as diffusion MRI was 
considered a secondary measurement to standard anatomic 
imaging techniques. Another potential limitation was the 
potential influence of geometric distortions on ADC measure-
ments. Woodworth et al (20) recently showed that post hoc 
non-linear distortion correction of diffusion MR images to 
high-resolution T2-weighted images can improve diffusion 
measurements in brain tumors, demonstrating that subtle 
distortions can cause significant differences in ADC measure-
ments. A similar approach could have been used in the present 
study to improve ADC measurements, even in patients with 
usable data (QC ≥3). Similarly, the use of a rigid-body image 
registration algorithm to align serial ADC maps to baseline 
ADC maps poses another potential limitation. Significant 
changes in mass effect from tumor growth or shrinkage, or 
intracranial pressure changes induced by changes in the 
extent of vasogenic edema may cause inaccuracies in the 
alignment between the diffusion MR datasets. A recent study 
by Ellingson et al (21) showed improved fDM performance 
in the context of bevacizumab therapy by using non-linear 
registration of ADC maps over time. It is conceivable that a 
similar approach may also have improved fDM performance 
in the context of the current study, which also involved similar 
therapies and registration challenges.
In conclusion, the present study suggests diffusion MRI 
data collected as part of a multicenter trial for brain tumors 
may be of limited value, due particularly to the wide variety in 
image quality across sites, vendors and acquisition protocols. 
In data deemed usable, fDM results showed similar trends but 
lower correlations compared with previous single-institution 
trials involving relatively high-quality diffusion data with 
homogeneous acquisition protocols. Stratification of survival 
using fDM metrics were substantially improved by examining 
a subset of patients with high quality DWI data, suggesting 
image quality may have a significant impact on fDM perfor-
mance. Future studies aimed at improving the consistency of 
image quality in multicenter trials are necessary for further 
advancement of diffusion MR biomarkers.
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